JP2021529746A5 - - Google Patents

Info

Publication number
JP2021529746A5
JP2021529746A5 JP2020572388A JP2020572388A JP2021529746A5 JP 2021529746 A5 JP2021529746 A5 JP 2021529746A5 JP 2020572388 A JP2020572388 A JP 2020572388A JP 2020572388 A JP2020572388 A JP 2020572388A JP 2021529746 A5 JP2021529746 A5 JP 2021529746A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
cycloalkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529746A (ja
JP7610985B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038908 external-priority patent/WO2020005888A1/en
Publication of JP2021529746A publication Critical patent/JP2021529746A/ja
Publication of JP2021529746A5 publication Critical patent/JP2021529746A5/ja
Application granted granted Critical
Publication of JP7610985B2 publication Critical patent/JP7610985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572388A 2018-06-26 2019-06-25 心臓サルコメア阻害剤 Active JP7610985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690249P 2018-06-26 2018-06-26
US62/690,249 2018-06-26
PCT/US2019/038908 WO2020005888A1 (en) 2018-06-26 2019-06-25 Cardiac sarcomere inhibitors

Publications (3)

Publication Number Publication Date
JP2021529746A JP2021529746A (ja) 2021-11-04
JP2021529746A5 true JP2021529746A5 (https=) 2022-07-04
JP7610985B2 JP7610985B2 (ja) 2025-01-09

Family

ID=67211971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572388A Active JP7610985B2 (ja) 2018-06-26 2019-06-25 心臓サルコメア阻害剤

Country Status (4)

Country Link
US (1) US12187712B2 (https=)
EP (1) EP3814343B1 (https=)
JP (1) JP7610985B2 (https=)
WO (1) WO2020005888A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) * 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
TW202339760A (zh) * 2022-01-28 2023-10-16 韓商鐘根堂股份有限公司 用於預防或治療心臟衰竭(hf)之組合物
EP4514355A1 (en) 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors
JP2025534288A (ja) * 2022-09-26 2025-10-15 エッジワイズ セラピューティクス， インコーポレイテッド １，４－ジヒドロキナゾリノン化合物およびその使用
EP4688756A1 (en) 2023-03-27 2026-02-11 Edgewise Therapeutics, Inc. Quinazoline dione compounds and uses thereof
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof
WO2025096779A2 (en) 2023-11-01 2025-05-08 Bristol Myers Squibb Company Methods of treatment with a myosin inhibitor using protein levels

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU2002365057A1 (en) 2001-12-21 2003-07-30 Cytokinetics, Inc. Compositions and methods for treating heart failure
ATE552236T1 (de) * 2003-01-14 2012-04-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
AU2004206955A1 (en) 2003-01-21 2004-08-05 Archemix Corp. Aptamer therapeutics useful in ocular pharmacotherapy
EP1605752B1 (en) 2003-03-27 2011-09-14 Cytokinetics, Inc. Sulfonamides for the treatment of congestive heart failure, their compositions and uses.
JP2007516176A (ja) 2003-06-20 2007-06-21 アムジエン・インコーポレーテツド ピペラジン誘導体及び使用方法
ES2522579T3 (es) 2004-06-17 2014-11-17 Cytokinetics, Inc. Compuestos, composiciones y métodos
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
WO2010033701A2 (en) 2008-09-19 2010-03-25 Genzyme Corporation Inhibitors of sphingosine kinase 1
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) * 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
AU2014362231B2 (en) 2013-12-11 2019-04-04 Biogen Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
EP4234017B1 (en) 2015-01-22 2026-04-15 MyoKardia, Inc. Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
CN108137517B (zh) 2015-10-02 2022-04-12 先正达参股股份有限公司 杀微生物的噁二唑衍生物
JP2019507110A (ja) * 2015-12-17 2019-03-14 シンジェンタ パーティシペーションズ アーゲー 殺微生物性オキサジアゾール誘導体
CN108368098B (zh) * 2015-12-18 2022-01-28 先正达参股股份有限公司 杀微生物的噁二唑衍生物
CA3022432A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
WO2017222951A1 (en) * 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
JP6681517B2 (ja) 2016-09-27 2020-04-15 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
JP2020023442A (ja) 2016-12-19 2020-02-13 住友化学株式会社 オキサジアゾール化合物及び植物病害防除方法
WO2018156883A1 (en) 2017-02-23 2018-08-30 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
CN110325517B (zh) 2017-02-28 2021-03-02 南京明德新药研发有限公司 螺环类化合物及其应用
CA3071948A1 (en) 2017-08-04 2019-02-07 MyoKardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
JP7438148B2 (ja) * 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
MX2021001380A (es) 2018-08-31 2021-05-27 Xenon Pharmaceuticals Inc Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos.
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
BR112022000523A2 (pt) 2019-07-17 2022-03-03 Cytokinetics Inc Polimorfo, métodos para preparar polimorfo, para tratar doença cardíaca, para tratar uma doença ou condição e para inibir o sarcômero cardíaco, e, composição farmacêutica
EP3999180B1 (en) 2019-07-17 2024-05-08 Cytokinetics, Inc. Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
RS65302B1 (sr) 2019-07-17 2024-04-30 Cytokinetics Inc Oralne formulacije inhibitora srčanog sarkomera
MX2023002024A (es) 2020-08-28 2023-05-10 Myokardia Inc Métodos de tratamiento con modulador de miosina.
CN117083275A (zh) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 心脏肌节抑制剂
PT4370116T (pt) 2021-07-16 2025-03-14 Cytokinetics Inc Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva
US12077069B2 (en) 2021-08-06 2024-09-03 Dorel Juvenile Group, Inc. Child restraint
EP4514355A1 (en) 2022-04-26 2025-03-05 MyoKardia, Inc. Methods of administering myosin inhibitors

Similar Documents

Publication Publication Date Title
JP2021529746A5 (https=)
JP2021535164A5 (https=)
JP2024508526A5 (https=)
JP2021529185A5 (https=)
JP2021511331A5 (https=)
JP2002529532A5 (https=)
JP2009535393A5 (https=)
RU2008119651A (ru) Производные дикарбоновых кислот и их применение
JP2007511563A (ja) 新規チアゾリジン−４−オン誘導体
CA2681972A1 (en) Substituted dibenzoic acid derivatives and use thereof
US20210122761A1 (en) 1,3-di-substituted ketene compound and application thereof
RU2012109545A (ru) Использование лигандов ppar дельта для лечения или предотвращения воспалений или заболеваний, связанных с метаболизмом/выработкой энергии
RU2011123672A (ru) Гетероароматические соединения для применения в качестве hif ингибиторов
RU2014107000A (ru) Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств
FR2562892A1 (fr) Nouveaux dihydropyridinyldicarboxylates amides et esters, utilisation de ces composes comme medicament, compositions pharmaceutiques comprenant de tels composes et procede pour la preparation de tels composes
US6673923B2 (en) Pyrazole antimicrobial agents
JP2021513543A5 (https=)
RU2008119465A (ru) Производные циклопропилуксусной кислоты и их применение
JP2024517769A5 (https=)
HU182461B (en) Process for producing new h-2 down-receptore antagonistic thiazole derivatives
FI4581034T3 (fi) 5-(3,4-difluoribentsyyli)-8-((1r,4r)-4-metyylisykloheksyyli)-6,9-diokso-2,5,8-triatsaspiro[3.5]nonaani-2-karbaldehydin kiteisiä muotoja
JP2007197324A (ja) ２，４，５−置換−１，３−アゾール誘導体
WO2004000813A1 (ja) フェノキシピリジン誘導体又はその塩
HU191753B (en) Process for preparing 5-acyl-2-/1h/-pyridinine deriva-tives
JP2022544803A5 (https=)